Parkinson's Disease Neuroprotection Clinical Trial

帕金森病(PD)是第二种最常见的神经退行性疾病。而一些有症状的人 虽然已经开发了治疗方法，但还没有确定可以阻止或减缓这种进行性疾病的治疗方法。为. 由于许多原因，我们认为开始一项或多项前瞻性临床试验是合适的 有希望的代理人来确定他们是否提供好处。这项申请的目的是作为临床中心参与 一项关于神经保护剂的合作研究。代理和协议将由NINDS指定。 加州大学旧金山分校在为帕金森病患者提供专科护理方面有很长的历史。加州大学旧金山分校帕金森氏病 临床研究中心(PDCRC)已经参与了一系列临床试验，以阐明神经学 帕金森病潜在的功能障碍，以及测试各种治疗帕金森病的新疗法。这项研究包括了一些 针对早期至晚期帕金森病患者的行业赞助治疗试验。大量多样化的当地人口提供了 为临床研究提供有动力的受试者的可靠来源。UCSF PDCRC在评价、选择中的经验 以下PD受试者使其成为潜在的多中心、前瞻性试验的理想候选者 神经保护性疗法。 理想的神经保护治疗应该是有效、廉价、耐受性好、安全、易于管理和 与普通药物几乎没有相互作用。在过去的十年中，对人体和实验的一些研究 动物已经表现出由小胶质细胞和一些炎性细胞介导的局部免疫反应。 细胞因子。此外，几种帕金森病的动物模型已经证明，抗炎药物可以干扰 与局部免疫反应有关，并可能保护多巴胺能神经元的功能。虽然是新兴的 我们建议，对帕金森病发病机制的了解可能为神经保护治疗提供一种替代方案。 抗炎药物将是治疗帕金森氏症的合理和实用的候选药物 神经保护试验。

Parkinson's disease (PD) is the second most common neurodegenerative disorder. While a number symptomatic therapies have been developed, no treatment has been identified that halts or slows this progressive disorder. For a number of reasons, we believe that it is appropriate to begin a prospective clinical trial of one or more of the more promising agents to determine whether they offer benefit. The aim of this application is to participate as a clinical center in a collaborative study of neuroprotective agents. The agents and protocol will be specified by NINDS. UCSF has a long history in providing subspecialty care for subjects with PD. The UCSF Parkinson's Disease Clinic & Research Center (PDCRC) has been involved in a number of clinical trials to elucidate the neurologic dysfunction underlying PD as well as testing a variety of novel treatments for PD. This research has included a number of industry sponsored treatment trials for subjects with early to advanced PD. A large diverse, local population provides a reliable source of motivated subjects for clinical research. The experience of the UCSF PDCRC in evaluating, selecting and following subjects with PD make it an ideal candidate for a multicenter, prospective trial of a potential neuroprotectant therapy. The ideal neuroprotective treatment should be effective, inexpensive, well tolerated, safe, easy to administer, and have few interactions with common medications. A number of studies over the last decade in humans and experimental animals have demonstrated a local immunologic response mediated by microglia and a number of inflammatory cytokines. Moreover, several animal models of PD have demonstrated that anti-inflammatory medications can interfere with the local immunologic response, and that they may preserve function of dopaminergic neurons. Although emerging understanding of the pathogenesis of PD may provide an alternative candidate for a neuroprotectant therapy, we propose that an anti-inflammatory medication would be a rational and practical candidate for the Parkinson's disease Neuroprotection Trial.